Figure 4

Liver results. Graphics of liver results in which: (W) refers to WISTAR stain, (S) refers to SHROB stain. (A) EPA:DHA 1:1, (B) EPA:DHA 2:1,(C) EPA:DHA 1:2. Equal letters, a, b, c, d, e means statistical differences among strains. (A) Liver samples of WISTAR rats no showed steatosis. Consequently, between WISTAR and SHROB statistically significant differences were observed in all treatment groups (EPA:DHA 1:1 p = 0.001, EPA:DHA 2:1 p = 0.001, EPA:DHA 1:2 p = 0.031). The graphics showns the grade of stetosi in SHROB rats, its location is shown in graphic (B) we can see how in SHROB rats steatosis tended to be periportal, but no statistically significant differences were found between treatment groups. (C) SHROB rats also showed greater lobular inflammation than Wistar. There were significant differences between strains in the EPA:DHA 2:1 and EPA:DHA 1:2 treatments (p = 0.025* and p = 0.02^{^}, respectively). (D) The presence of microgranulomas was higher in SHROB rats than in Wistar, and the differences were significant in three tretament groups: EPA:DHA 2:1 (p = 0.005a). In SHROB fewer microgranulomas were present in the EPA:DHA 1:1 and EPA:DHA 1:2 treatments, but there were no significant differences with other groups. (E) We found lipogranulomas in the Wistar EPA:DHA 2:1 group and in all the groups of SHROB rats, with significant differences between strains for EPA:DHA 1:1 (p < 0.001), EPA:DHA 2:1 (p = 0.001), EPA:DHA 1:2 (p = 0.002). (F) Portal inflammation was present in both Wistar and SHROB rats but differences were only significant between strains in the EPA: DHA 1:1 treatment (p < 0.001). No differences between treatments were found in the same strain.